Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
EQRx, Inc. EQRX
$1.68
+$0.02 (1.20%)
На 18:04, 12 мая 2023
+197.62%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
815967023.00000000
-
week52high
6.05
-
week52low
1.58
-
Revenue
0
-
P/E TTM
4
-
Beta
0.00000000
-
EPS
-0.35000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 ноя 2022 г. в 13:30
Описание компании
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinical and pre-clinical stage assets, which comprise Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which is in Phase II clinical trials in patients with metastatic breast cancer; EQ176, an anti-programmed death-1 antibody that is in Phase III trials for the treatment of patients with primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor that is in various Phase I trials. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| JP Morgan | Neutral | 16 авг 2022 г. | |
| Goldman Sachs | Buy | 13 июн 2022 г. | |
| Cowen & Co. | Outperform | 22 апр 2022 г. | |
| Jefferies | Buy | 18 мар 2022 г. | |
| JP Morgan | Underweight | Neutral | 14 ноя 2022 г. |
| Jefferies | Hold | Buy | 11 ноя 2022 г. |
| Goldman Sachs | Neutral | Buy | 11 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| AH Equity Partners LSV I, L.L.C. | A | 1574510 | 8246 | 01 янв 2023 г. |
| AH Equity Partners LSV I, L.L.C. | A | 2642897 | 13842 | 01 янв 2023 г. |
| AH Equity Partners LSV I, L.L.C. | A | 2401418 | 12577 | 01 янв 2023 г. |
| Nallicheri Melanie | A | 530335 | 2777 | 01 янв 2023 г. |
| Nallicheri Melanie | A | 1041108 | 5453 | 01 янв 2023 г. |
| AH Equity Partners Bio II, L.L.C. | A | 1574510 | 8246 | 01 янв 2023 г. |
| AH Equity Partners Bio II, L.L.C. | A | 2642897 | 13842 | 01 янв 2023 г. |
| AH Equity Partners Bio II, L.L.C. | A | 2401418 | 12577 | 01 янв 2023 г. |
| BERNS PAUL L | A | 86344 | 453 | 01 янв 2023 г. |
| MEANWELL CLIVE | A | 43172 | 226 | 01 янв 2023 г. |
Новостная лента
EQRx to Present at the 41st Annual J.P. Morgan Healthcare Conference
GlobeNewsWire
03 янв 2023 г. в 08:00
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and expanding access to innovative medicines for some of the most prevalent disease areas, including cancer and immune-inflammatory conditions, today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 4:30 p.m. PST / 7:30 p.m. EST.
Here's Why EQRx, Inc. (EQRX) is Poised for a Turnaround After Losing 23% in 4 Weeks
Zacks Investment Research
13 дек 2022 г. в 11:17
The heavy selling pressure might have exhausted for EQRx, Inc. (EQRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
EQRx, Inc. (EQRX) Q3 2022 Earnings Call Transcript
Seeking Alpha
13 ноя 2022 г. в 11:45
EQRx, Inc. (NASDAQ:EQRX ) Q3 2022 Earnings Conference Call November 10, 2022 8:00 AM ET Company Participants Neil Swami - Head, Investor Relations Melanie Nallicheri - President and Chief Executive Officer Jami Rubin - Chief Financial Officer Eric Hedrick - Chief Physician Executive Conference Call Participants Steve Scala - Cowen Chris Schott - JPMorgan Operator Good morning and welcome to the EQRx Third Quarter 2022 Financial Results Conference Call. [Operator Instructions] Please be advised that this conference call is being recorded.
A Biotech Steps Back From Bold Plan to Drop Drug Prices. A Stunning Selloff.
Barrons
10 ноя 2022 г. в 16:51
Share of EQRx plunged 28.6% after the drugmaker said it would sell two cancer drugs at market prices, instead of the cut-rate prices it had promised.
Why EQRx Shares Dropped 28.62% on Thursday
The Motley Fool
10 ноя 2022 г. в 16:43
The company suspended trials for one of its lead therapies.